Epigenomics AG

EANS-Adhoc: Ad Hoc Announcement pursuant of §15 WpHG (German Securities Trading Act): Epigenomics AG: Licensing Partner Quest Diagnostics Introduces Colorectal Cancer Blood Test in the U.S.

  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.

New Products/Molecular diagnostics


Berlin, January 11, 2010 - Epigenomics AG (ISIN: DE000A0BVT96), a cancer molecular diagnostics company, informs that Quest Diagnostics Incorporated, Madison, NJ, U.S.A., today introduced its laboratory developed blood test for aiding the detection of colorectal cancer in the United States. The test was independently developed by Quest Diagnostics based on Epigenomics´ proprietary DNA methylation biomarker Septin9 and certain proprietary technologies that were licensed to Quest Diagnostics in 2008. The introduction follows the successful completion of the clinical validation of this laboratory developed test in November 2009 and the release of the test for offering to doctors and patients in December 2009.

Physicians in the United States may order the test through a Quest Diagnostics regional laboratory. With the introduction of this test, Epigenomics continues executing its dual business model of non-exclusive licensing and direct commercialization of its cancer molecular diagnostic biomarkers and products.

End of Ad hoc

Further Information

For further information please see today´s press release by Quest Diagnostics at http://ir.questdiagnostics.com/phoenix.zhtml?c=82068&p=irol-news

Epigenomics legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward- looking statements contained herein as a result of new information, future events or otherwise.

end of announcement                               euro adhoc

Further inquiry note:

Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Tel: +49 30 24345 368

Branche: Biotechnology
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade

Original-Content von: Epigenomics AG, übermittelt durch news aktuell

Weitere Meldungen: Epigenomics AG

Das könnte Sie auch interessieren: